Nordea Investment Management AB Has $592.89 Million Holdings in Becton, Dickinson and Company $BDX

Nordea Investment Management AB cut its position in Becton, Dickinson and Company (NYSE:BDX) by 4.0% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,231,514 shares of the medical instruments supplier’s stock after selling 133,995 shares during the quarter. Nordea Investment Management AB’s holdings in Becton, Dickinson and Company were worth $592,886,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in BDX. S Bank Fund Management Ltd grew its position in shares of Becton, Dickinson and Company by 27.0% in the 3rd quarter. S Bank Fund Management Ltd now owns 37,657 shares of the medical instruments supplier’s stock valued at $7,048,000 after acquiring an additional 8,000 shares during the period. Sumitomo Mitsui Trust Group Inc. lifted its stake in Becton, Dickinson and Company by 1.1% in the 3rd quarter. Sumitomo Mitsui Trust Group Inc. now owns 696,028 shares of the medical instruments supplier’s stock valued at $130,276,000 after purchasing an additional 7,739 shares during the last quarter. First Horizon Corp bought a new position in Becton, Dickinson and Company during the third quarter worth about $57,000. MGO One Seven LLC increased its position in Becton, Dickinson and Company by 20.6% during the third quarter. MGO One Seven LLC now owns 13,298 shares of the medical instruments supplier’s stock worth $2,489,000 after buying an additional 2,274 shares during the last quarter. Finally, Citizens Financial Group Inc. RI raised its stake in Becton, Dickinson and Company by 20.0% in the third quarter. Citizens Financial Group Inc. RI now owns 3,640 shares of the medical instruments supplier’s stock valued at $681,000 after buying an additional 606 shares during the period. 86.97% of the stock is owned by institutional investors.

Becton, Dickinson and Company Trading Down 0.0%

Shares of BDX stock opened at $202.65 on Tuesday. The stock has a market cap of $57.74 billion, a P/E ratio of 34.76, a price-to-earnings-growth ratio of 2.24 and a beta of 0.23. Becton, Dickinson and Company has a 1 year low of $162.29 and a 1 year high of $251.99. The company has a current ratio of 1.11, a quick ratio of 0.64 and a debt-to-equity ratio of 0.69. The stock has a 50 day simple moving average of $193.62 and a 200 day simple moving average of $188.59.

Becton, Dickinson and Company (NYSE:BDX) last posted its quarterly earnings data on Thursday, April 14th. The medical instruments supplier reported $4.10 EPS for the quarter. The firm had revenue of $5.32 billion for the quarter. Becton, Dickinson and Company had a return on equity of 16.42% and a net margin of 7.68%.Becton, Dickinson and Company has set its FY 2026 guidance at 14.750-15.050 EPS. On average, research analysts predict that Becton, Dickinson and Company will post 14.43 earnings per share for the current fiscal year.

Becton, Dickinson and Company Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Wednesday, December 31st. Shareholders of record on Monday, December 8th were issued a $1.05 dividend. The ex-dividend date of this dividend was Monday, December 8th. This represents a $4.20 annualized dividend and a yield of 2.1%. This is an increase from Becton, Dickinson and Company’s previous quarterly dividend of $1.04. Becton, Dickinson and Company’s payout ratio is 72.04%.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on BDX shares. Bank of America increased their price target on Becton, Dickinson and Company from $190.00 to $207.00 and gave the company a “neutral” rating in a research note on Monday, January 5th. Stifel Nicolaus raised their target price on shares of Becton, Dickinson and Company from $210.00 to $215.00 and gave the stock a “buy” rating in a research note on Wednesday, January 7th. Morgan Stanley upped their price target on shares of Becton, Dickinson and Company from $197.00 to $210.00 and gave the company an “overweight” rating in a research note on Tuesday, December 2nd. Wall Street Zen cut shares of Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a report on Saturday, November 8th. Finally, Argus boosted their price objective on Becton, Dickinson and Company from $220.00 to $230.00 in a report on Monday, September 15th. Four analysts have rated the stock with a Buy rating and nine have given a Hold rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $207.64.

Insider Activity at Becton, Dickinson and Company

In other news, Director Bertram L. Scott sold 217 shares of the company’s stock in a transaction that occurred on Friday, November 7th. The shares were sold at an average price of $176.58, for a total transaction of $38,317.86. Following the completion of the sale, the director owned 35,816 shares of the company’s stock, valued at approximately $6,324,389.28. This represents a 0.60% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, EVP Michael David Garrison sold 629 shares of Becton, Dickinson and Company stock in a transaction that occurred on Wednesday, December 17th. The shares were sold at an average price of $196.03, for a total transaction of $123,302.87. Following the completion of the transaction, the executive vice president directly owned 13,105 shares in the company, valued at $2,568,973.15. This trade represents a 4.58% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 1,052 shares of company stock valued at $201,235 over the last 90 days. Corporate insiders own 0.40% of the company’s stock.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.